ALK amplification and rearrangements are recurrent targetable events in congenital and adult glioblastoma.
Anne-Florence BlandinRoss M GiglioMaya Srikanth GrahamGuadalupe GarciaSeth MalinowskiJared K WoodsShakti RamkissoonLori RamkissoonFrank P B DubiosKathleen SchoolcraftJessica W TsaiDayle K WangRobert JonesJayne VogelzangKristine PeltonSarah BeckerFiona WatkinsonClaire SinaiElizabeth F CohenMatthew A BookerMichael Yevgeniy TolstorukovVeerle HaemelsLiliana Christova GoumnerovaKaren D WrightMark W KieranKatie Pricola FehnelDavid A ReardonArnault Tauziède-EspariatRishi R LullaBenjamin CarcamoStanley ChaleffAlain CharestFrederik De SmetAzra H LigonAdrian M DubucMelanie PagesPascale VarletPatrick Yung WenBrian M AlexanderSusan N ChiSanda AlexandrescuRalf KittlerRobert BachooPratiti BandopadhayayRameen BeroukhimKeith L LigonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
These findings support use of brain-penetrant ALK inhibitors in clinical trials across infant, pediatric, and adult GBMs.